|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
5,780,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.3302 - $0.3302 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Phio Pharmaceuticals is developing therapeutics that use its INTASYL technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
2,500 |
6,500 |
22,216 |
Total Buy Value |
$0 |
$2,275 |
$14,195 |
$22,362 |
Total People Bought |
0 |
1 |
2 |
2 |
Total Buy Transactions |
0 |
1 |
4 |
12 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bitterman Robert J |
Interim Executive Chairman |
|
2022-11-16 |
4 |
B |
$1,750.00 |
$1,750 |
D/D |
1 |
1 |
2.73 |
- |
|
Bitterman Robert J |
Director |
|
2022-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
65,826 |
|
- |
|
Bradford Patricia A |
Director |
|
2022-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Kontulis Caitlin |
Secretary & VP Finance & Admin |
|
2022-03-01 |
4 |
D |
$0.82 |
$3,293 |
D/D |
(4,011) |
103,815 |
|
- |
|
Dispersyn Gerrit |
President & CEO |
|
2022-03-01 |
4 |
D |
$0.82 |
$7,351 |
D/D |
(8,954) |
212,327 |
|
- |
|
Dispersyn Gerrit |
President & CEO |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
126,000 |
221,281 |
|
- |
|
Bitterman Robert J |
Director |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
25,826 |
|
- |
|
Cauwenbergh Geert |
Director |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
32,822 |
|
- |
|
Lockshin Curtis |
Director |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,366 |
|
- |
|
Kontulis Caitlin |
Secretary & VP Finance & Admin |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
68,000 |
107,826 |
|
- |
|
Freeman Jonathan E |
Director |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,364 |
|
- |
|
Ferrara Robert L |
Director |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
23,000 |
|
- |
|
Dorman H. Paul |
Director |
|
2022-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,370 |
|
- |
|
Dispersyn Gerrit |
President & CEO |
|
2021-08-16 |
4 |
B |
$1.63 |
$9,780 |
D/D |
6,000 |
95,281 |
2.81 |
- |
|
Dispersyn Gerrit |
President & CEO |
|
2021-03-04 |
4 |
B |
$2.56 |
$5,000 |
D/D |
1,953 |
89,281 |
2.81 |
- |
|
Dispersyn Gerrit |
President & CEO |
|
2021-03-03 |
4 |
B |
$3.03 |
$7,575 |
D/D |
2,500 |
87,328 |
2.81 |
- |
|
Ferrara Robert L |
Director |
|
2021-03-03 |
4 |
B |
$3.15 |
$2,148 |
D/D |
682 |
13,000 |
2.31 |
- |
|
Dispersyn Gerrit |
President & CEO |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
68,450 |
84,828 |
|
- |
|
Cauwenbergh Geert |
Director |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
22,822 |
|
- |
|
Kontulis Caitlin |
Secretary & VP Finance & Admin |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
34,600 |
39,826 |
|
- |
|
Lockshin Curtis |
Director |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,366 |
|
- |
|
Freeman Jonathan E |
Director |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,364 |
|
- |
|
Dorman H. Paul |
Director |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,370 |
|
- |
|
Bitterman Robert J |
Director |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
15,826 |
|
- |
|
Ferrara Robert L |
Director |
|
2021-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
12,318 |
|
- |
|
238 Records found
|
|
Page 2 of 10 |
|
|